Trial Profile
A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioNTech
- 12 Mar 2024 Planned End Date changed from 19 Mar 2024 to 9 Dec 2024.
- 12 Mar 2024 Planned primary completion date changed from 19 Mar 2024 to 9 Dec 2024.
- 20 Oct 2023 Planned End Date changed from 28 Jun 2024 to 19 Mar 2024.